Ovarian cancer
- PMID: 19793610
- DOI: 10.1016/S0140-6736(09)61338-6
Ovarian cancer
Abstract
The standard initial management of epithelial ovarian cancer consists of surgical staging, operative tumour debulking including total abdominal hysterectomy and bilateral salpingo-oophorectomy, and administration of six cycles of intravenous chemotherapy with carboplatin and paclitaxel. Extensive and largely retrospective experience has shown that optimum surgical debulking to leave residual tumour deposits that are less than 1 cm in size is associated with improved patient outcomes. However, 75% of patients present with advanced (stage III or IV) disease and, although more than 80% of these women benefit from first-line therapy, tumour recurrence occurs in almost all these patients at a median of 15 months from diagnosis. Second-line treatments can improve survival and quality of life but are not curative. Advances in screening and understanding of molecular pathogenesis of ovarian cancer and development of novel targeted therapies (eg, bevacizumab) and practical intraperitoneal techniques for drug delivery are most likely to improve patient outcomes.
Similar articles
-
Advances in the management of epithelial ovarian cancer.J Reprod Med. 2005 Jun;50(6):426-38. J Reprod Med. 2005. PMID: 16050567 Review.
-
[Analysis of risk factors for epithelial ovarian cancer recurrence].Ai Zheng. 2003 Nov;22(11):1197-200. Ai Zheng. 2003. PMID: 14613652 Chinese.
-
[Treatment and prognostic factors for stage IV epithelial ovarian cancer].Zhonghua Fu Chan Ke Za Zhi. 2000 Apr;35(4):200-3. Zhonghua Fu Chan Ke Za Zhi. 2000. PMID: 11776158 Chinese.
-
Prognostic significance of second-look laparotomy for surgically confirmed early-stage epithelial ovarian cancer: a multicenter retrospective study.Int J Clin Oncol. 2003 Feb;8(1):40-4. doi: 10.1007/s101470300005. Int J Clin Oncol. 2003. PMID: 12601541
-
[Epithelial ovarian cancer].Ther Umsch. 2007 Jul;64(7):375-80. doi: 10.1024/0040-5930.64.7.375. Ther Umsch. 2007. PMID: 17948754 Review. German.
Cited by
-
Role of hsa‑miR‑105 during the pathogenesis of paclitaxel resistance and its clinical implication in ovarian cancer.Oncol Rep. 2021 May;45(5):84. doi: 10.3892/or.2021.8035. Epub 2021 Apr 13. Oncol Rep. 2021. PMID: 33846814 Free PMC article.
-
Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases.Gynecol Oncol. 2013 Feb;128(2):364-70. doi: 10.1016/j.ygyno.2012.10.015. Epub 2012 Oct 22. Gynecol Oncol. 2013. PMID: 23099104 Free PMC article.
-
MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.Oncotarget. 2016 May 3;7(18):26516-34. doi: 10.18632/oncotarget.8530. Oncotarget. 2016. PMID: 27049921 Free PMC article.
-
Identification of a Prognostic Signature for Ovarian Cancer Based on the Microenvironment Genes.Front Genet. 2021 May 13;12:680413. doi: 10.3389/fgene.2021.680413. eCollection 2021. Front Genet. 2021. PMID: 34054929 Free PMC article.
-
Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines.J Ovarian Res. 2016 Oct 18;9(1):65. doi: 10.1186/s13048-016-0278-z. J Ovarian Res. 2016. PMID: 27756418 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical